JPMorgan Chase & Co. Has Lowered Expectations for Travere Therapeutics (NASDAQ:TVTX) Stock Price

JPMorgan Chase & Co. has reduced its price target for Travere Therapeutics (NASDAQ:TVTX) from $44.00 to $41.00 but maintained an “overweight” rating, indicating a potential upside of 53.56% from the previous close. The consensus among analysts is a “Moderate Buy” with an average target price of $38.38. Despite recent insider selling, major institutions like Vanguard and State Street have increased their stakes in the biopharmaceutical company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin